Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 425809 in cognitive impairment due to Alzheimer's disease
jRCT2080223912Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing BI 425809 with Placebo (2 arms). Started May 2018; status: completed.
02
Drugs
iclepertin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223912.